AMCS
14.8.2024 12:56:29 CEST | Business Wire | Press release
AMCS, a global leader of sustainability software for foundational industries, and EQT Private Equity are pleased to announce that EQT X and EQT Future (jointly "EQT Private Equity") will acquire a majority stake in the Company. The co-founder, management, and other existing investors, including existing majority investor Insight Partners, as well as Clearlake Capital, Highland Europe and the Ireland Strategic Investment Fund, are expected to retain minority stakes.
Founded in 2003, and headquartered in Ireland, AMCS serves resource-intensive industries, including waste management, recycling, transportation, manufacturing, and utilities. With its industry leading SaaS platform, which includes Enterprise Resource Planning, recycling, transport, and EHSQ & ESG software, AMCS is strongly positioned to support its customers’ needs and shift towards a more circular economy. AMCS’ market is growing quickly thanks to secular tailwinds including the growth in complexity associated with shifting to greater circularity in supply chains, as well as cloud software adoption trends, and increasing regulatory and sustainability reporting.
AMCS' solutions help to deliver increased performance and efficiency in its customers’ operations, while also supporting them to deliver on their sustainability goals and meet regulatory requirements. AMCS’ customers include some of the largest waste management and recycling companies globally, as well as blue-chip manufacturing customers. With over 1,300 employees across Europe, North America and Australasia, AMCS serves over 3800 customers, across 80 countries, and helps manage more than 700,000 vehicles globally.
The partnership with AMCS represents a highly thematic investment for both EQT X and EQT Future. EQT Private Equity will contribute its extensive experience in software value creation and impact acceleration to support the Company’s growth and sustainability ambitions. More than two billion tons of waste is generated annually, resulting in one billion tons of CO2 and 3.2 percent of global emissions1, hence the clear need for solutions that can eventually support the transition to a circular economy. AMCS’ solutions sit at the heart of its customers’ operations and, given its leadership position, have tremendous potential to improve resource efficiency for the industry as a whole.
Performance Sustainability: Sustainability That Means Business
AMCS’ Performance Sustainability Suite is the operating system for foundational industries that makes sustainability and profitability possible. The suite manages the running of day-to-day operations such as contracts and pricing, logistics and transportation, materials and resources, health and safety, and sustainability intelligence. The AMCS Performance Sustainability Suite drives growth and profitability, optimizes efficiency and safety, powers corporate sustainability initiatives, and prepares businesses for the circular economy and the future. With AMCS, businesses can improve performance and scale more easily, enabling foundational industry professionals to leave the planet in a better way than they found it.
Jimmy Martin, co-founder and CEO, AMCS, said: “On behalf of AMCS, I'd like to express our deepest gratitude to EQT, for aligning with our vision of empowering sustainability for organizations globally and championing the circular economy. Their backing is instrumental in supporting the transformative work we do. I’d like to also thank our dedicated, long-standing investors Insight Partners, Clearlake Capital, Highland Europe, and the Ireland Strategic Investment Fund. These pillars of our capital structure have shown once again their unwavering faith in AMCS through their renewed support. Our shared commitment with our investors is the fuel that drives AMCS to solidify our pivotal role as a leader in Performance Sustainability.”
Robert Maclean, Partner in the EQT Private Equity advisory team, said: “We have followed the progress of AMCS closely for many years and have been hugely impressed by what it has achieved, establishing itself as a clear market leader and delivering continuous innovation on behalf of its customers. We strongly believe that AMCS has a fantastic opportunity to further support the circular economy and drive a greater share of recycling within the waste industry. We are very pleased to be partnering with AMCS’ co-founder and CEO Jimmy Martin as well as his entire team, to deliver on an exciting, shared vision for growth.”
Simon Griffiths, Head of the EQT Future advisory team, said: “Our investment in AMCS is strongly aligned with EQT Future’s focus on leading businesses, where the market opportunity and the very strong decarbonisation impact angle support a long-term investment horizon. We believe that AMCS is clearly positioned to be a long-term winner as the world shifts to a circular economy, and we look forward to supporting AMCS to help drive this trend and deliver on its growth ambitions."
Richard Wells, Managing Director at Insight Partners, said: “Since our initial investment in 2015, Insight has had the privilege of supporting AMCS as it scaled into a global market leader driving positive change towards a more circular economy. We look forward to deepening our support of AMCS, led by co-founder and CEO Jimmy Martin, in partnership with EQT as the business continues to innovate and grow."
The transaction is subject to customary conditions and approvals. It is expected to close before Q1 2025.
William Blair & Company served as exclusive financial advisor to AMCS. Willkie Farr & Gallagher served as legal counsel to Insight Partners. Arma Partners served as exclusive financial advisor and Clifford Chance as legal counsel to EQT.
About EQT
EQT is a purpose-driven global investment organization with EUR 246 billion in total assets under management (EUR 133 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership. Learn more at: www.eqtgroup.com. Follow EQT on LinkedIn, X, YouTube and Instagram.
About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of December 31, 2023, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.
About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.
Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 3800 customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.
At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at: www.amcsgroup.com
1 World Bank; Climate Watch; the World Resource Institute.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813785675/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
